KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Assets Average (2016 - 2025)

Historic Assets Average for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $4.9 billion.

  • Alnylam Pharmaceuticals' Assets Average rose 1625.78% to $4.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.9 billion, marking a year-over-year increase of 1625.78%. This contributed to the annual value of $4.6 billion for FY2025, which is 1408.27% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Assets Average stood at $4.9 billion for Q4 2025, which was up 1625.78% from $4.7 billion recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Assets Average peaked at $4.9 billion during Q4 2025, and registered a low of $3.3 billion during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Assets Average averaged around $3.8 billion, with its median value being $3.6 billion (2021).
  • In the last 5 years, Alnylam Pharmaceuticals' Assets Average skyrocketed by 4251.71% in 2021 and then tumbled by 195.78% in 2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Assets Average (Quarter) stood at $3.6 billion in 2021, then dropped by 0.48% to $3.5 billion in 2022, then rose by 8.29% to $3.8 billion in 2023, then grew by 10.12% to $4.2 billion in 2024, then rose by 16.26% to $4.9 billion in 2025.
  • Its Assets Average stands at $4.9 billion for Q4 2025, versus $4.7 billion for Q3 2025 and $4.4 billion for Q2 2025.